Prostate cancer: Watchful wait or vaccinate?February 04, 2008Researchers develop successful test vaccine that prevents development of prostate cancer PHILADELPHIA - Researchers at the University of Southern California have developed a prostate cancer vaccine that prevented the development of cancer in 90 percent of young mice genetically predestined to develop the disease. In the February 1 issue of Cancer Research, they suggest the same strategy might work for men with rising levels of PSA (prostate specific antigen), a potential diagnostic indicator of prostate cancer. "By early vaccination, we have basically given these mice life-long protection against a disease they were destined to have," said the study's lead investigator, W. Martin Kast, Ph.D., a professor of Molecular Microbiology & Immunology and Obstetrics & Gynecology at the Norris Comprehensive Cancer Center. "This has never been done before and, with further research, could represent a paradigm shift in the management of human prostate cancer."
Now, men with rising PSA levels but no other signs of cancer are advised "watchful waiting" - no treatment until signs of the cancer appear, Kast says. "But what if instead of a watchful wait, we vaccinate" That could change the course of the disease." The study findings also represent a new way to think about the use of therapeutic prostate cancer vaccines, Kast says. Vaccines now in testing are designed to treat men whose cancers are advanced and unresponsive to therapy, and results have offered limited clinical benefit, he says. This novel approach targets the precancerous state with the aim of preventing cancer from developing, he says. The Kast team's preventive vaccine is designed to mount an immune response against prostate stem cell antigen (PSCA), the protein target of some therapeutic vaccines under development. PSCA, a membrane protein, is over-expressed in about one-third of early-stage prostate cancers, but expression ramps up in all prostate tumors as they grow and advance. PSCA is also expressed at low-levels in normal prostate gland tissue as well as in the bladder, colon, kidney and stomach. The researchers created a prime-boost vaccination scheme using two kinds of vaccines and tested it in 8-week-old mice that were genetically altered to develop prostate cancer later in life. The first vaccine simply delivered a fragment of DNA that coded for PSCA, thus producing an influx of PSCA protein to alert the immune system. The booster shot, given two weeks later, used a modified horse virus to deliver the PSCA gene. "Confronting the immune system in two different ways forces it to mount a strong response," Kast said. In the experimental group, two of 20 mice developed prostate cancer at the end of one year, and by contrast, all control mice had died of the disease. Researchers found that mice in the experimental group had all developed very small tumors that did not progress. "There were tiny nodules of prostate cancer in the mice that were surrounded by an army of immune system cells," Kast said. "The vaccination turned the cancer into a chronic, manageable disease." The vaccination strategy also works with other antigens, Kast says. The researchers recently tried another prostate cancer membrane target and found that after 1.5 years, 65 percent of experimental mice were still alive, and of those that died, the suspected cause was old age. Crucially, investigators further found that treated mice did not develop autoimmune disease, a side effect that could develop if the vaccine had also targeted PSCA expression in normal cells. "Theoretically, the vaccine could produce a response in any tissue that expresses the antigen, but the fact that PSCA is expressed in such low levels in normal tissue may prevent that complication," he said. Still, studies in humans are needed to ensure autoimmunity does not develop, Kast says. "We feel this is a very promising approach," he said. "With just two shots, the vaccine will prime immune cells to be on the lookout for any cell that over-expresses PSCA." American Association for Cancer Research Science News and Science Current Events Tag Cloud This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size. Salmonella Liquid Crystal Cortisol Blood transfusion Ischemic Stroke Sleeping Sickness MicroRNA Language Epithelial Cells Asteroid Arctic sea ice Fungi Mars Express Fragile X Syndrome AIDS vaccine X-ray Infants Premature Birth Mosquitoes Mosquito AIDS Carbon Footprint Anxiety Disorders Biofuel Liver Cirrhosis
See More: Science News Tags | |||||||||||||||||||||
|
Related Prostate Cancer Current Events and Prostate Cancer News Articles Predicting the return of prostate cancer: New Johns Hopkins study betters the odds of success Cancer experts at Johns Hopkins say a study tracking 774 prostate cancer patients for a median of eight years has shown that a three-way combination of measurements has the best chance yet of predicting disease metastasis. Second gene linked to familial testicular cancer Specific variations or mutations in a particular can gene raise a man's risk of familial, or inherited, testicular germ-cell cancer, the most common form of this disease. Researchers pinpoint a new enemy for tumor-suppressor p53 Researchers at The University of Texas M. D. Anderson Cancer Center have identified a protein that marks the tumor suppressor p53 for destruction, providing a potential new avenue for restoring p53 in cancer cells. Report: Prostate cancer screening has yet to prove its worth The recent release of two large randomized trials suggests that if there is a benefit of screening, it is, at best, small. Selenium intake may worsen prostate cancer in some, study reports Higher selenium levels in the blood may worsen prostate cancer in some men who already have the disease, according to a study by researchers at Dana-Farber Cancer Institute the University of California, San Francisco. Prostate Cancer Translational Research in Europe meeting: Search for biomarkers continues Collaboration in prostate cancer translational research in Europe is not only vital to sustain the progress achieved in recent years but also to streamline current efforts between researchers and clinicians and avoid duplication or overlaps. Dr. Ronald Lewis Couples' treatment for sexual problems on the agenda for sexual medicine experts Couples' treatment for sexual problems and other innovative approaches to improving sexual health for men and women are on the agenda of sexual medicine experts. BRIT1 allows DNA repair teams access to damaged sites Like a mechanic popping the hood of a car to get at a faulty engine, a tumor-suppressing protein allows cellular repair mechanisms to pounce on damaged DNA by overcoming a barrier to DNA access. Autonomous robot detects shrapnel Bioengineers at Duke University have developed a laboratory robot that can successfully locate tiny pieces of metal within flesh and guide a needle to its exact location -- all without the need for human assistance. Green tea may affect prostate cancer progression According to results of a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research, men with prostate cancer who consumed the active compounds in green tea demonstrated a significant reduction in serum markers predictive of prostate cancer progression. More Prostate Cancer Current Events and Prostate Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||